Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis

This study has been terminated.
(No subject enrolled since 2009)
Sponsor:
Information provided by (Responsible Party):
Richard Burt, MD, Northwestern University
ClinicalTrials.gov Identifier:
NCT00282425
First received: January 24, 2006
Last updated: December 14, 2012
Last verified: December 2012
  Purpose

Scleroderma is disease believed to be due to immune cells, cells which normally protect the body but are now causing damage to the body. There has not been any treatment that has been effective in treating this disease. The likelihood of progression of the disease to severe disability and death is high. This study is designed to examine whether treating patients with high dose Cyclophosphamide and Fludarabine (drugs which reduce the function of your immune system) and CAMPATH-1H (a protein that kills the immune cells that are thought to be causing the disease), followed by return of blood stem cells that have been previously collected from patients brother or sister will stop or reverse the disease. The purpose of the Cyclophosphamide, Fludarabine and CAMPATH-1H is to decrease immune system. The purpose of the stem cell infusion is to restore blood production, which will be severely impaired by the Cyclophosphamide, Fludarabine and CAMPATH-1H, and to produce a normal immune system that will no longer attack the body.


Condition Intervention Phase
Scleroderma
Biological: Hematopoietic stem cell transplantation
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis

Resource links provided by NLM:


Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Survival; Disease improvement;Time to disease progression [ Time Frame: 5 years after transplant ] [ Designated as safety issue: Yes ]

Enrollment: 8
Study Start Date: May 2005
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Allogeneic Hematopoietic stem cell transplantation
Allogeneic Hematopoietic stem cell transplantation will be performed on eligible patients
Biological: Hematopoietic stem cell transplantation
Allogeneic Hematopoietic stem cell transplantation

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Patient Inclusion Criteria:

  1. Age 18 to 55 years old
  2. An established diagnosis of scleroderma (84)
  3. Diffuse cutaneous scleroderma with involvement proximal to the elbow or knee and a Rodnan score (see Appendix III) of > 14 (85)

And one of the following:

  1. DLCO < 80% of predicted or decrease in lung function (TLC, DLCO or FEV1) of 10% or more over 12 months
  2. Active alveolitis on bronchoalveolar lavage
  3. Pulmonary fibrosis or alveolitis on CT scan or CXR
  4. Elevated ESR greater than or equal to 25mm/hour confirmed on a second occasion at least two weeks apart without evidence of active infectious process.
  5. Abnormal EKG (low QRS voltage, or ventricular hypertrophy) or left ventricle (LV) diastolic dysfunction (expressed by an inverted E/A ratio which represents early and late filling of the LV during atrial contraction) or LV wall thickness
  6. Since pulmonary disease independent of skin score (NEJM, 2006, 345:25 2655-2709) carries a poor prognosis, patient may be enroled for only lung involvement defined as active alveolitis on BAL or ground-glass opacity on CT, a DLCO < 80% predicted or decrease in lung function (TLC), DLCO, FVC) of 10% or more in last 12 months.

Patient Exclusion Criteria:

  1. Poor performance status (ECOG > or =2) at the time of entry, unless due to disease.
  2. Significant end organ damage such as:

    1. LVEF <40% or deterioration of LVEF during exercise test on MUGA or echocardiogram
    2. Untreated life-threatening arrhythmia
    3. Active ischemic heart disease or heart failure
    4. DLCO less than 45% of predicted value, unless due to disease.
    5. Pulmonary hypertension (estimated systolic pulmonary arterial pressure >40 mmHg by Doppler echocardiography or measurement by pulmonary arterial catheter)
    6. Serum creatinine > 2.0 mg/dl
    7. Liver cirrhosis, transaminases >3x of normal limits or bilirubin >2.0 unless due to Gilberts disease
  3. HIV positive
  4. Uncontrolled diabetes mellitus or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment
  5. Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as (but not limited to) head and neck cancer, or stage I or II breast cancer will be considered on an individual basis.
  6. Positive pregnancy test, inability or unable to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a side effect of therapy
  7. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible
  8. Inability to give informed consent
  9. Age <18 or > 55 years old

Donor Inclusion Criteria:

  1. Donor must be a HLA identical sibling or HLA matched cord blood donor
  2. If donor is HLA matched sibling, donor must be > 18 years of age and less than 50 years old
  3. If multiple HLA matched donors are available, preference will be given to same sex, same CMV status, or in the case of cord blood higher nucleated cell count
  4. If donor is HLA matched cord blood, cord blood stem cells will be obtained from the New York Blood Center Cord Blood Registry (Tel 212-570-3230) which is an internationally recognized registry or, if a match is not available, from Stemcyte (626-821-9860) which is a commercial registry that specializes in minority donors. One unit of HLA matched cord blood unit will be infused on day zero

Donor Exclusion Criteria:

  1. Age > 50 years old or <18 years old
  2. HIV positive
  3. Active ischemic heart disease or heart failure
  4. Acute or chronic active hepatitis
  5. Uncontrolled diabetes mellitus or any other illness that in the opinion of the investigators would jeopardize the ability of the donor to tolerate stem cell collection
  6. Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as (but not limited to) head and neck cancer, or stage I or II breast cancer will be considered on an individual basis.
  7. Positive pregnancy test
  8. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible
  9. Major hematological abnormalities such as platelet count less than 100,000/ul, ANC less than 1000/ul
  10. If donor is sibling must collect a minimum of 2. 106CD34+ cells/kg to proceed to transplant
  11. If donor is cord blood unit(s) then a minimum number of nucleated cells available must be more than 2 x 107 /kg. To achieve this number of nucleated cells, two units of HLA matched cord blood may be utilized. (Wagner JE Blood. 2005 Feb 1;105(3):1343-7)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00282425

Locations
United States, Illinois
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Richard Burt, MD
Investigators
Principal Investigator: Richard Burt, MD Northwestern University
  More Information

No publications provided

Responsible Party: Richard Burt, MD, MD, Northwestern University
ClinicalTrials.gov Identifier: NCT00282425     History of Changes
Other Study ID Numbers: DIAD Scl.Allo2005
Study First Received: January 24, 2006
Last Updated: December 14, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Scleroderma, Systemic
Scleroderma, Diffuse
Sclerosis
Connective Tissue Diseases
Skin Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on July 22, 2014